Captain T Cell Secures €20 Million in Equity Financing to Advance Autologous and Allogeneic TCR-T Therapies for Solid Tumors

Nov 18, 2025 11:28 CST Updated 11:28

Captain T Cell

T Cell Therapy Developer

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

On November 17, 2025, Captain T Cell, a biotechnology company focused on developing the next generation of TCR-T cell therapies for solid tumors, announced that it has completed an equity financing round participated by both new and existing investors. The equity funding from this round, combined with previously secured government grants, provides the company with a total budget of 20 million euros (approximately 23.19 million US dollars).Used forAdvancing its best-in-class autologous project CTC127 into the Phase I clinical data readout stage，And advance its pioneering allogeneic "off-the-shelf" solid tumor treatment program towards clinical trial readiness.

This round of financing was led by Springboard Health Angels and Pluton Asset Holding AG, with follow-up investments from Sintra Limited, Technologiegründerfonds Sachsen, and existing investors i&i Biotech Fund, HIL-INVENT, and Brandenburg Kapital.

Funds will drive the company's core project———Autologous TCR-T Cell Therapy Targeting MAGE-A4 Positive Solid TumorsCTC127 Enters First-in-Human Phase I Clinical Trial.The trial is led by Professor Antonia Busse of Charité – Berlin University of Medicine and conducted in collaboration with eight top oncology centers across Germany. It plans to recruit patients with various advanced MAGE-A4 positive solid tumors, including lung cancer, bladder cancer, gastroesophageal cancer, ovarian cancer, and head and neck cancer. CTC127 is based on the company's proprietary multifunctional engineering.Toolbox, which can functionally "armor" T cells, enhancing their anti-tumor activity, persistence, and tolerance within the solid tumor microenvironment.

At the same time, the company has utilized its first-in-class allogeneic TCR-T cell platform to achieve complete remission of solid tumors in animal models and will further advance it to a clinical trial-ready state. In addition, the company also plans to expand this best-in-class proprietary toolbox to in vivo T-cell therapy applications.

Dr. Felix Lorenz, CEO of Captain T Cell, stated"Despite the severe financing environment, we have gained extensive support from investors, which fully demonstrates the competitive advantage of the company's next-generation T-cell therapy platform in terms of best-in-class and first-in-class. It also enables us to advance these therapies for the benefit of cancer patients. Our best-in-class autologous project CTC127 is about to enter a fully funded phase."TOMATA Clinical Trial, the first-in-class allogeneic TCR-T platform is also moving towards clinical readiness. We are optimistic that this best-in-class Toolbox technology will gain clinical validation in the upcoming trials and subsequently expand to off-the-shelf treatment solutions."

Dr. Andreas Schmidt of Springboard Health Angels said, "We are delighted to co-lead the latest round of financing for Captain T Cell. The company’s core project, CTC127, has the potential to offer an effective and safe treatment option for solid tumor patients in urgent need of new therapies. With funding secured and extending through Phase I readout, Captain T Cell is well-positioned for a significant value inflection point."

Dr. Theis Terwey, Chief Representative of Pluton Asset Holding AG, commented: "MAGE-A4 is a commercially validated and risk-controllable target. Existing preclinical data convincingly demonstrate that Captain T Cell’s Toolbox enhancement strategy is conceptually superior to currently marketed solid tumor cell therapies, providing strong evidence for the company to achieve competitive efficacy in large indications."

Reference: Company Announcement

Scan to join the group

Mastering CAR-T Therapy, Stem Cell Therapy, Gene

Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs